Carter Davis, MD
Hematology & Oncology · New Orleans, LANPI 1407146418
Payments from drug & device makers
Across 311 payments — averaging $5017.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Beigene, Ltd.$795K
- Genentech, Inc.$540K
- Beone Medicines Ltd.$63K
- AbbVie$46K
- Beone Medicines USA, Inc.$39K
- Astrazeneca UK Limited$32K
- plus $45K from 29 others
What the payments were for
- Consulting fees$36,34759%
- Speaking & faculty fees$12,57021%
- Travel & lodging$5,4519%
- Food & beverage$6,66711%
- Education$1160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Beigene, Ltd. | 55 | $795,223 |
| Genentech, Inc. | 71 | $539,822 |
| Beone Medicines Ltd. | 9 | $62,875 |
| AbbVie | 29 | $46,237 |
| Beone Medicines USA, Inc. | 19 | $39,405 |
| Astrazeneca UK Limited | 4 | $32,126 |
| ADC Therapeutics America, Inc. | 15 | $12,335 |
| E.r. Squibb & Sons, L.L.C. | 9 | $9,553 |
| Regeneron | 19 | $7,820 |
| Servier Pharmaceuticals LLC | 3 | $2,638 |
| CTI Biopharma Corp. | 1 | $2,500 |
| Ipsen Biopharmaceuticals, Inc | 2 | $2,146 |
| Genentech USA, Inc. | 3 | $1,936 |
| Bristol Myers Squibb | 21 | $1,671 |
| Taiho Oncology, Inc. | 1 | $1,100 |
| Johnson & Johnson | 2 | $1,098 |
| Kyowa Kirin, Inc. | 3 | $336 |
| Gilead(2 entities) | 9 | $264 |
| Jazz Pharmaceuticals Inc. | 2 | $259 |
| Seagen Inc. | 2 | $205 |
| Beigene USA, Inc. | 10 | $196 |
| Incyte Corporation | 2 | $140 |
| Janssen Scientific Affairs, LLC | 5 | $138 |
| Sanofi | 2 | $102 |
| GSK | 1 | $95 |
| Genmab U.S., Inc. | 2 | $58 |
| Pierre Fabre Pharmaceuticals, Inc. | 1 | $53 |
| Karyopharm Therapeutics Inc. | 1 | $49 |
| Novartis | 2 | $46 |
| AstraZeneca | 1 | $32 |
| Amgen | 1 | $30 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $26 |
| Stemline Therapeutics Inc. | 1 | $17 |
| Epizyme, Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,560,559 in reported general payments places this provider in the 95th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VenclextaVenetoclax | 181 | $1,108,917 |
| JakafiRuxolitinib Phosphate | 57 | $876,277 |
| RevlimidLenalidomide | 46 | $782,761 |
| OnuregAzacitidine | 25 | $556,926 |
| ImbruvicaIbrutinib | 35 | $534,495 |
| Lenalidomide | 35 | $505,355 |
| BrukinsaZanubrutinib | 31 | $449,169 |
| CalquenceAcalabrutinib Maleate | 31 | $437,513 |
| InqoviDecitabine/Cedazuridine | 24 | $195,187 |
| PromactaEltrombopag Olamine | 15 | $170,384 |
| SprycelDasatinib | 11 | $105,502 |
| EliquisApixaban | 123 | $85,539 |
| Venclexta Starting PackVenetoclax | 11 | $35,403 |
| XareltoRivaroxaban | 17 | $22,288 |
| Posaconazole | 28 | $18,298 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVenclexta | $46,237 | $1,108,917181 claims |
| Incyte CorporationJakafi | $140 | $876,27757 claims |
| Bristol Myers SquibbRevlimid | $1,671 | $782,76146 claims |
| E.r. Squibb & Sons, L.L.C.Onureg, Sprycel | $9,553 | $662,42836 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $26 | $534,49535 claims |
| Beigene USA, Inc.Brukinsa | $196 | $449,16931 claims |
| AstraZenecaCalquence | $32 | $437,51331 claims |
| Taiho Oncology, Inc.Inqovi | $1,100 | $195,18724 claims |
| NovartisPromacta, Entresto | $46 | $179,62628 claims |
| Johnson & JohnsonXarelto, Procrit | $1,098 | $28,38628 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 183 hematology & oncology providers in Louisiana.
Other hematology & oncology in New Orleans
- Marc MatranaNew Orleans$4.6M
- Pedro BarataNew Orleans$4.2M
- Maissaa JanbainNew Orleans$1.5M
- Lingling duNew Orleans$1.2M
- John ColeNew Orleans$896K
- Cindy LeissingerNew Orleans$432K
- Furhan YunusNew Orleans$422K
- David MorrisonNew Orleans$313K
- Stefan GrantNew Orleans$261K
- Michelle LochNew Orleans$232K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.